Skip Navigation

Diversion Quarterly Q4 2021

Diversion Quarterly Q4 2021

Kit Check is sharing data from its Bluesight™ for Controlled Substances platform on a quarterly basis to provide insight into the types of diversions and investigations that may be occurring in hospital pharmacies. The following information is as of December 31st, 2021. Data was pulled from health systems across the United States.

Key Takeaways

There continues to be a rise in diversion despite employee confidence that medications are harder to access.

  • Fentanyl has stabilized in terms of variance growth but the data suggest that there was a significant jump in reports of Methadone (5.5% increase) and Ketamine (5%). Since the approved use of Ketamine in 2019, the availability of this drug has increased.

Download the latest information about our suite of medication intelligence products by using the button below.

Want to read the rest?